Literature DB >> 31427296

Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.

Tobias Lahmer1, Gonzalo Batres Baires2, Markus Heilmaier2, Roland M Schmid2, Fritz Sörgel3,4, Martina Kinzig3, Wolfgang Huber2, Ulrich Mayr2, Sebastian Rasch2.   

Abstract

Isavuconazole plasma concentrations were measured before and after sustained low-efficiency dialysis (SLED) treatment in 22 critically ill adult patients with probable invasive aspergillosis and underlying hematological malignancies. Isavuconazole levels were significantly lower after SLED treatment (5.73 versus 3.36 μg/ml; P < 0.001). However, even after SLED treatment, isavuconazole concentrations exceeded the in vivo MICs for several relevant Aspergillus species.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  SLED; critically ill; invasive aspergillosis; isavuconazole; therapeutic drug monitoring

Mesh：

Substances：

Year:  2019        PMID： 31427296      PMCID： PMC6811396          DOI： 10.1128/AAC.01162-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Daily hemodialysis and the outcome of acute renal failure.

Authors:  Helmut Schiffl; Susanne M Lang; Rainald Fischer
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

3.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Authors:  Laura L Kovanda; Ruta Petraitiene; Vidmantas Petraitis; Thomas J Walsh; Amit Desai; Peter Bonate; William W Hope
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

Review 4.  Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.

Authors:  J Denis; M-P Ledoux; Y Nivoix; R Herbrecht
Journal:  J Mycol Med       Date:  2018-03-11       Impact factor: 2.391

5.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.

Authors:  David Andes; Laura Kovanda; A Desai; Therese Kitt; M Zhao; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

6.  Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes.

Authors:  Gilles Clermont; Christopher G Acker; Derek C Angus; Carl A Sirio; Michael R Pinsky; John P Johnson
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

Review 7.  Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.

Authors:  M-P Ledoux; J Denis; Y Nivoix; R Herbrecht
Journal:  J Mycol Med       Date:  2018-03-16       Impact factor: 2.391

8.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Authors:  A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely
Journal:  Clin Microbiol Infect       Date:  2018-03-12       Impact factor: 8.067

9.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

10.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Authors:  Frederic Tissot; Samir Agrawal; Livio Pagano; Georgios Petrikkos; Andreas H Groll; Anna Skiada; Cornelia Lass-Flörl; Thierry Calandra; Claudio Viscoli; Raoul Herbrecht
Journal:  Haematologica       Date:  2016-12-23       Impact factor: 9.941
View more
  2 in total

1.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Host-directed therapy in foals can enhance functional innate immunity and reduce severity of Rhodococcus equi pneumonia.

Authors:  Angela I Bordin; Noah D Cohen; Steve Giguère; Jocelyne M Bray; Londa J Berghaus; Brenton Scott; Rena Johnson; Magnus Hook
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.